First-in-human clinical trial for disease-modifying Parkinson’s treatment commences

A United Kingdom-based clinical-stage biotech company has announced commencement of a first-in-human clinical trial of a selective central nervous system-penetrant compound to treat Parkinson’s disease.

In a press release, Mission Therapeutics said that dosing has been completed in the first cohort of healthy volunteers in a multipart adaptive trial evaluating safety, tolerability, pharmacokinetics and brain penetration of MTX325.

Single ascending, multiple dose ascending and elderly healthy volunteer cohorts are planned to be included in the trial this year, while those diagnosed with PD are expected to be the focus of the trial in 2025, Mission said in the release.

“We are delighted to have brought this second USP30 inhibitor into clinical development,” Suhail Nurbhai, MBChB MRCP, chief medical officer at Mission Therapeutics, said in the release. “We look forward to progressing this compound rapidly through initial clinical testing and aim to demonstrate its potentially beneficial clinical profile later this year.”